EMA Authorised: Dzuveo (sufentanil citrate) — Laboratoire Aguettant

View source ↗

Summary

The EMA has authorised Dzuveo (sufentanil citrate) from Laboratoire Aguettant for pain management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Dzuveo (sufentanil citrate)

Snippet

Status: Authorised. Therapeutic area: Pain. MAH: Laboratoire Aguettant. Decision date: 31/07/2026